Trial Profile

Ethinylestradiol/cyproterone versus pioglitazone + flutamide + metformin in adolescent girls with androgen excess.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Flutamide (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Ethinylestradiol/cyproterone
Indications Hyperandrogenism
Focus Pharmacodynamics
Acronyms DIO

08 Oct 2023 Results of post hoc pooled analysis assessing the pooled pre-treatment data of 65 adolescent girls with PCOS-without-obesity in three reported studies (ISRCTN 45546616; 29234515; 11062950) and the results of 24 adolescent girls with PCOS-without-obesity, who received pioglitazone (7.5 mg/d for 1 year) as part of a randomized combination treatment (with spironolactone and metformin) in two reported studies (29234515; 11062950), published in the Journal of Endocrinological Investigation.
18 Jun 2013 Results presented at the 95th Annual Meeting of the Endocrine Society.
30 Jun 2011 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com